Physician profile
Douglas Wayne Orr
NPI 1194767061
$13,681.64
in general payments reported to CMS, 2019-2025
20 companies · $13K in 2025
The $13K reported for 2025 was more than what 83% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.71 · 2021: $23.75 · 2023: $755 · 2024: $75.63 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $13K · Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,425.60 |
| Food and Beverage | $174.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Pharma Sas | $12,769.21 | 2025 | |
| Stryker Corporation | $755.34 | 2023 | Cascadia Interbody System |
| Siemens Medical Solutions USA, INC. | $57.71 | 2019 | |
| Astellas Pharma US INC | $40.78 | 2024 | Xtandi, Padcev |
| Aveo Pharmaceuticals, INC. | $20.95 | 2024 | |
| Abbvie INC. | $13.90 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Eisai INC. | $11.83 | 2021 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.